Ezetimibe
Zetia
Ezetimibe (Zetia) is a longevity & bioregulators research compound. Blocks the NPC1L1 sterol transporter in the small intestine, cutting absorption of both dietary and biliary cholesterol. Completely different mechanism from a statin, which is why the two stack rather than overlap.
Ezetimibe quick facts
| Reported research dose | 10mg daily |
| Route | Oral |
| Frequency | 1x |
| Half-life | ~22 hours |
| Forms | Oral |
| Evidence level | IMPROVE-IT showed added event reduction on top of a statin |
The right add-on when a statin alone doesn't get ApoB to target, or when statin dose is limited by muscle symptoms. Roughly another 20% LDL reduction on top. Plant sterols work on the same transporter at a fraction of the potency.
How Ezetimibe works
Blocks the NPC1L1 sterol transporter in the small intestine, cutting absorption of both dietary and biliary cholesterol. Completely different mechanism from a statin, which is why the two stack rather than overlap.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Ezetimibe
Buy Ezetimibe at AlgoRx →The evidence for Ezetimibe
Graded by what exists behind each claim.
✅ Clinically validated
- Approved, and its key trial answered a question that had been open for years. IMPROVE-IT (18,144 patients) added ezetimibe to a statin after acute coronary syndrome and showed a further reduction in cardiovascular events — modest in size but statistically clear.
- Why that mattered: it demonstrated that lowering LDL by a non-statin mechanism also lowers risk, supporting the view that LDL itself is causal rather than the statin doing something else.
📊 Correlative data
- Wide use, mostly as an add-on when a statin alone is insufficient or as a substitute when statins are not tolerated. Notably free of the muscle complaints that limit statins, which is the practical reason it gets used.
🧪 Theoretical / extrapolated
- Inhibits the NPC1L1 transporter in the intestinal brush border, blocking absorption of both dietary and biliary cholesterol.
- Blocking absorption triggers compensation — the liver upregulates its own cholesterol synthesis in response, which caps the effect at roughly 18–20% LDL reduction on its own.
- That compensation is exactly why the statin combination works better than either alone: the statin blocks the synthesis the ezetimibe would otherwise provoke. It is one of the cleanest examples of rational drug pairing in cardiology.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Ezetimibe actually does
Ezetimibe is the rare drug that found its own target: the protein was identified by working backwards from a compound that already worked. That protein is Niemann-Pick C1-Like 1, a 13-transmembrane sterol transporter on the brush-border membrane of the jejunal enterocyte, and also on the canalicular membrane of human hepatocytes, where it reclaims cholesterol from bile.
What NPC1L1 actually does, now that the structures exist. Cryo-electron microscopy of human NPC1L1 shows the mechanism: cholesterol binds in a hydrophobic tunnel through the N-terminal domain, and the transporter then internalizes by clathrin-mediated endocytosis, carrying the sterol into the cell Hu 2021. Dimeric structures add how the two protomers arrange Long 2021. So absorption is not passive diffusion across a membrane — it is a protein swallowing a molecule and then swallowing itself. Ezetimibe locks that machine: it binds NPC1L1 and prevents the conformational change and internalization step, so cholesterol arrives at the brush border and is not taken in.
Which is why 10 mg is the entire dose and 20 mg does nothing extra. This is a stoichiometric conformational block on a finite number of transporters in a defined tissue. Once they are occupied, more drug has nothing left to occupy. Nearly every other lipid drug has a dose-response curve; this one has a ceiling, and the ceiling is the transporter population.
And then the liver does the rest, which is the half people forget. Blocking absorption depletes hepatic cholesterol; the hepatocyte responds by upregulating the LDL receptor through SREBP-2; LDL receptors clear more LDL particles from plasma. Ezetimibe lowers LDL by the same final common pathway a statin does — more LDL receptors — reached from the opposite direction. A statin blocks synthesis, ezetimibe blocks absorption, and both end at the receptor. That is why they are additive and why adding ezetimibe to a statin roughly repeats the receptor upregulation the statin already caused.
Cell, rodent, human — and where it stops
Step one, structure and cells, where the mechanism is now settled at near-atomic resolution Hu 2021 Long 2021.
Step two, human pharmacokinetics, from a study that is old and excellent. In healthy male subjects given radiolabelled drug, ezetimibe was rapidly absorbed and extensively conjugated; approximately 78% of the radioactive dose was recovered in feces and 11% in urine by 240 hours, with total recovery averaging 89%, and the glucuronide conjugate was the main circulating metabolite Patrick 2002. That last clause is the whole pharmacology: the glucuronide is not a waste product being disposed of, it is the predominant circulating form.
Step three, outcomes, and the analysis worth quoting is the one by baseline LDL. In 17,999 post-acute-coronary-syndrome patients, adding ezetimibe to a statin gave consistent hazard ratios across baseline LDL cholesterol strata: 0.92 (95% CI 0.80–1.05) at 50 to under 70 mg/dL, 0.93 (0.87–1.01) at 70 to under 100, and 0.94 (0.86–1.03) at 100 to 125, with normalized relative risk reductions of 21%, 16% and 13% respectively Oyama 2021. Read the direction of that: the relative benefit was LARGEST in the group that started with the LOWEST LDL. That is the lipid hypothesis behaving exactly as stated — benefit tracks the absolute reduction achieved, and there is no floor below which lowering stops helping.
The obstacle, named. Every outcome number above comes from secondary prevention after an acute coronary syndrome, on a statin background. The Vault reader is usually in primary prevention, often young, often statin-naive or statin-intolerant. The LDL reduction transfers — it is a transporter, not a population effect — but the event reduction does not transfer arithmetically, because absolute risk reduction depends on absolute risk. The same relative benefit on a tenth of the baseline risk is a tenth of the benefit.
Ezetimibe pharmacokinetics — how much of it actually gets in
The card says ~22 hours. The interesting thing is how a drug with almost no systemic ambition manages a 22-hour half-life, and the answer is a loop.
What happens to it, in order. Ezetimibe is absorbed into the enterocyte and immediately glucuronidated there — by UGT enzymes in the intestinal wall, before it ever reaches the liver. The glucuronide is secreted into bile and delivered straight back to the intestinal lumen, where its target sits. The conjugate is at least as active at NPC1L1 as the parent, so the body is repeatedly returning the active drug to its own site of action. That is enterohepatic recirculation working as a delivery system rather than as a clearance inefficiency, and it explains both the long half-life and why systemic exposure stays low: the drug spends its life shuttling between gut and bile. Recovery was 78% fecal, 11% urinary Patrick 2002, which is what a biliary-recycled drug looks like on a mass balance.
The oral barrier, inverted. For almost every other drug in this cohort, first-pass metabolism is a loss. Here it is the activation and targeting step. There is no meaningful CYP involvement, which is why ezetimibe has an unusually clean interaction profile for a lipid drug — and why the variation that does exist tracks UGT and transporter genotypes rather than cytochromes González-Iglesias 2024.
The numbers that matter for scheduling. A ~22 hour half-life with once-daily dosing means near-complete steady state within four to five days, and the lipid effect is therefore fully expressed at two weeks — which is why a repeat lipid panel earlier than that measures the titration and not the drug. Because the target is in the gut lumen and the recycling is biliary, timing relative to meals is not critical, which is unusual and worth knowing.
The comparator, and the interaction it explains. There is no injectable ezetimibe and there could not usefully be one: an injected dose would bypass the enterocyte where the drug is glucuronidated and where its target lives. The route is not a convenience, it is the mechanism. It also explains the one interaction that matters: bile acid sequestrants bind the biliary glucuronide and interrupt the recycling loop, which is why they are separated by hours rather than taken together.
What would have to be true, and how you would know it was not
Three predictions with markers, directions and windows. The third is the mechanism-derived cost the marketing does not mention.
1. ApoB should fall by roughly the same percentage as LDL cholesterol, and a divergence is informative. Order a lipid panel and ApoB at baseline and at 6 weeks. Ezetimibe works by upregulating the LDL receptor, which clears whole particles — so particle count and cholesterol content should move together. Prediction: LDL down about 18–20% as monotherapy, ApoB down similarly. If LDL falls and ApoB does not, the particles got smaller rather than fewer, which is a worse outcome wearing a better number, and it is invisible without ordering both.
2. Lp(a) should not move, and knowing that in advance prevents a wasted expectation. Lp(a) is genetically determined and is not cleared appreciably by the LDL receptor pathway. Prediction: unchanged. Order it once, ever, at baseline — it is a lifetime number and it changes the risk arithmetic that decides whether this drug is worth taking at all in primary prevention.
3. The prediction that cuts against it: fat-soluble vitamin absorption should fall, because NPC1L1 is not cholesterol-selective. In a Caco-2 model, ezetimibe altered micelle structure and reduced NPC1L1-mediated absorption of vitamin E and vitamin K1 Aizawa 2025. That is a cell model, and it is a directly mechanism-derived cost rather than a scare: the same transporter handles other lipophilic micelle passengers. Order vitamin D (25-hydroxy) at baseline and at 6 months as the practical proxy, since it is the fat-soluble vitamin most people already track. Prediction: a small decline in people whose intake is marginal, and nothing in people whose intake is good. Whether this matters clinically at 10 mg in humans has never been established, and saying so is more useful than either ignoring it or inflating it.
What nobody has tested yet
Four questions with no published answer.
Nobody has measured fat-soluble vitamin status in long-term human ezetimibe users. The transporter mechanism predicts an effect and a cell model shows one for vitamins E and K1 Aizawa 2025. Serum vitamin E, vitamin K status and 25-hydroxy vitamin D in a cohort on ten years of therapy is an ordinary observational study on a drug taken by millions, and it has not been reported.
Nobody has tested ezetimibe monotherapy for outcomes in statin-intolerant primary prevention. The outcome data is on a statin background in secondary prevention Oyama 2021. The population most likely to be prescribed this alone is precisely the one with no outcome data, and the trial has never been run because the drug is generic and nobody is paying for it.
Nobody has related UGT and transporter genotype to actual LDL response in practice. The pharmacogenetics have been evaluated González-Iglesias 2024. Whether that variation explains the well-known spread in individual response — some people drop 25%, some barely 10% — is an obvious question with a partial answer sitting unused.
Nobody has asked whether the hepatic NPC1L1 population matters in humans. NPC1L1 is expressed on the human hepatocyte canalicular membrane as well as in the gut, and the structural work describes the transporter generally rather than tissue by tissue Hu 2021. What blocking the hepatic pool does to biliary cholesterol and to gallstone risk in a person is unresolved, and it is the one plausible long-term effect nobody is looking for.
Ezetimibe — its own safety story, not its class's
Ezetimibe is one of the best-tolerated drugs in this cohort, and the honest safety page says why the risks are small rather than listing them generically.
Why systemic toxicity is unlikely by design. The drug is glucuronidated in the enterocyte and spends its life recycling between gut and bile, with 78% recovered in feces Patrick 2002. Systemic exposure to the free parent is low, there is no meaningful CYP metabolism, and therefore no long interaction list. A drug that never really leaves the enterohepatic circulation has limited opportunity to do systemic harm, and the clinical record matches that prediction.
The muscle question, stated fairly. Myalgia is reported on ezetimibe, including in some patients who could not tolerate a statin. Mechanistically there is no obvious route — ezetimibe does not inhibit the mevalonate pathway and does not deplete ubiquinone the way a statin arguably does. The most defensible reading is that some of this is nocebo carried over from statin experience and some may be real and unexplained. The useful practical point is that adding ezetimibe is the standard way to reach an LDL target when statin dose is muscle-limited, and roughly another 18–20% off LDL without touching the statin dose is the reason.
The liver, in proportion. Transaminase elevations are uncommon on ezetimibe alone and modestly more frequent in combination with a statin, which is why a baseline and one follow-up are reasonable and continuous monitoring is not. The relevant test is a CMP, and the relevant timing is before starting and once at around three months.
The nutrient interaction is the one this page adds. NPC1L1 carries other lipophilic passengers, and in a cell model ezetimibe reduced absorption of vitamins E and K1 Aizawa 2025. The practical, low-cost response is to take fat-soluble vitamins with a meal separate from the dose, and to check vitamin D once at six months rather than to worry about it continuously. Ezetimibe is a prescription medicine; nothing here is medical advice or a recommendation for use.
Sources read for this page
- Hu M, et al. Structural insights into the mechanism of human NPC1L1-mediated cholesterol uptake. Science Advances 2021 · PMID 34272236
- Long T, et al. Structures of dimeric human NPC1L1 provide insight into mechanisms for cholesterol absorption. Science Advances 2021 · PMID 34407950
- Oyama K, et al. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. Journal of the American College of Cardiology 2021 · PMID 34620406
- Aizawa H, et al. Ezetimibe Alters Micelle Structure and Reduces Niemann-Pick C1-like 1-Mediated Absorption of Vitamins E and K1 in CaCo-2 Cells. Journal of Pharmaceutical Sciences 2025 · PMID 40054527
- Patrick JE, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metabolism and Disposition 2002 · PMID 11901097
- González-Iglesias E, et al. Evaluation of the role of metabolizing enzymes and transporter variants in ezetimibe pharmacokinetics. Frontiers in Pharmacology 2024 · PMID 39484171
Ezetimibe — safety, from the human record
Not a prediction. This one has been studied in people. What follows is drawn from the human record — trials, labels and pharmacovigilance — rather than from what the mechanism implies. Where the way it is used here differs from what was studied, the card says so. How evidence is graded here →
What the mechanism predicts
Derived from the molecule, not a trial.
- Blocking the NPC1L1 sterol transporter in the small intestine cuts absorption of both dietary and biliary cholesterol. The liver compensates by making more, which is precisely why this stacks with a statin instead of overlapping — each drug blocks the other's escape route.
- Because it acts in the gut lumen and is minimally systemic, the mechanism predicts remarkably little. There is no mevalonate-pathway involvement, so none of the statin muscle reasoning transfers.
What has actually been reported
- One of the best-tolerated lipid drugs there is. Diarrhea and abdominal discomfort are the common complaints; myopathy and transaminase rises are reported mainly when it is combined with a statin, and at rates close to statin monotherapy.
- IMPROVE-IT showed that adding it to a statin produced a further reduction in cardiovascular events proportionate to the further LDL reduction — which is the clearest single piece of evidence that the benefit tracks the particle count rather than the drug.
How to reduce the risk
Same mechanism as the prediction.
- Judge it on ApoB at 6–8 weeks and stop it if the number did not move. Its whole case is a measurable particle reduction, so an unmeasured course of it is pointless.
- Take it at a consistent time relative to any bile acid sequestrant or fiber supplement.
What it does to your bloodwork
A fact about the assay.
- ApoB, before and 6–8 weeks after — the effect is fast and either it moved the particle count or it did not.
- ALT/AST if it is being run alongside a statin.
What it overlaps with
- Bile acid sequestrants bind it and cut its absorption; separate the doses. Ciclosporin raises ezetimibe exposure and ezetimibe raises ciclosporin.
- With a statin this is additive by design, not redundant.
Don't run this if
- Moderate or severe hepatic impairment.
- Pregnancy and breastfeeding, in combination with a statin.
The honest unknown
- Monotherapy outcome data is thin — almost all of the hard-endpoint evidence comes from adding it to a statin. Whether ezetimibe alone delivers proportionate benefit is inferred from the LDL relationship rather than demonstrated directly.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Ezetimibe — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Ezetimibe moves on your bloodwork
Expected direction, not a measured one.
- ApoB (Apolipoprotein B) — ↓ expected to fall
ApoB is the number that matters here, not LDL-C. ApoB counts the actual atherogenic particles; LDL-C estimates the cholesterol inside them, and the two diverge in exactly the people who most need treating — high triglycerides, metabolic syndrome, small dense LDL.
What to do: Baseline and again at 8–12 weeks. If your lab will only run a standard lipid panel, ask for ApoB specifically. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Falling total and LDL cholesterol is the drug working. Note that LDL-C is usually CALCULATED rather than measured, and the calculation becomes unreliable when triglycerides are high.
What to do: Fast beforehand if triglycerides are part of what you are tracking. - Lipoprotein(a) — Lp(a) — ◆ worth watching
Lipoprotein(a) is largely genetic and statins do not lower it — some data suggests they nudge it slightly up. It is worth knowing once in your life because it changes how aggressively the rest is worth treating.
What to do: Test it once. If it is normal you never need it again; if it is high, that is a real finding about your risk that no lifestyle change will move. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver enzymes can rise on a statin. Clinically meaningful hepatotoxicity is rare, and routine monitoring was dropped from most guidelines — but a baseline is still worth having.
What to do: Baseline, then only if symptoms appear. - Coenzyme Q10 — ↓ expected to fall
Statins inhibit the same pathway that makes CoQ10, so a fall is the predicted mechanistic consequence. Whether that causes the muscle symptoms people attribute to it is genuinely unsettled.
What to do: Worth testing only if you have muscle symptoms — otherwise it is a number without a decision attached.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Ezetimibe in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Ezetimibe
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Ezetimibe — frequently asked questions
What is Ezetimibe?
Ezetimibe (Zetia) is a longevity & bioregulators research compound. Blocks the NPC1L1 sterol transporter in the small intestine, cutting absorption of both dietary and biliary cholesterol. Completely different mechanism from a statin, which is why the two stack rather than overlap.
Is the full Ezetimibe protocol on this page?
The reported research dose is on this page, along with how Ezetimibe works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Ezetimibe?
Ezetimibe has an approximate half-life of ~22 hours, which is part of what determines how often it's dosed.
What's the evidence behind Ezetimibe?
Current evidence level: IMPROVE-IT showed added event reduction on top of a statin. Ezetimibe is offered for research purposes only and is not an approved medicine.
Ezetimibe inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Ezetimibe is used for
Ezetimibe appears under 2 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Ezetimibe is the arm with mortality data of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.